XI LIU to Biomarkers, Tumor
This is a "connection" page, showing publications XI LIU has written about Biomarkers, Tumor.
Connection Strength
0.052
-
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011 Jun; 4(6):818-28.
Score: 0.026
-
Involvement of microRNAs in lung cancer biology and therapy. Transl Res. 2011 Apr; 157(4):200-8.
Score: 0.025